Thank you for visiting Nature.com. The browser version you are using has limited CSS support. For the best experience, we recommend that you use an updated browser (or disable Compatibility Mode in Internet Explorer). In the meantime, to ensure continued support, we will render the site without styles and JavaScript.
Peptides and proteins are widely used to treat a variety of diseases, but they usually have to be injected and their effect is short-lived. These shortcomings of native structures can be eliminated with the help of molecular engineering, but this is a difficult task. Molecular engineering techniques, originally applied to insulin and now successfully applied to several biopharmaceuticals, require the derivatization of peptides and proteins from fatty acids. The specific characteristics and location of the attached fatty acids may provide different elongation mechanisms. In addition, this technology may provide a long half-life after oral administration of peptide drugs, may alter the distribution of peptides, and may have the potential for tissue targeting. With the inherent safety of fatty acids and well-defined chemical properties, this technology provides a versatile approach to peptide and protein drug discovery.
All prices are net. VAT will be added later at checkout. Tax calculations will be made at the checkout.
Muttenthaler, M., King, GF, Adams, DJ & Alewood, PF Trends in peptide drug discovery. Muttenthaler, M., King, GF, Adams, DJ & Alewood, PF Trends in peptide drug discovery. Muttenthaler, M., King, G.F., Adams, D.J. and Alevud, P.F. Trends in peptide drug discovery. Muttenthaler, M., King, GF, Adams, DJ & Alewood, PF 多肽药物发现的趋势。 Muttenthaler, M., King, GF, Adams, DJ & Alewood, PF Muttenthaler, M., King, G.F., Adams, D.J. and Alevud, P.F. Trends in peptide drug discovery. National The opening of the drug pastor. 20, 309–325 (2021). This review focuses on current and future aspects of peptide drug discovery.
Müller, TD, Blüher, M., Tschöp, MH & DiMarchi, RD Anti-obesity drug discovery: advances and challenges. Müller, TD, Blüher, M., Tschöp, MH & DiMarchi, RD Anti-obesity drug discovery: advances and challenges. Müller, T.D., Blucher, M., Chop, M.H. and DiMarchi, R.D. Anti-obesity drug discovery: progress and challenges. Müller, TD, Blüher, M., Tschöp, MH & DiMarchi, RD 抗肥胖药物发现：进展和挑战。 Müller, TD, Blüher, M., Tschöp, MH & DiMarchi, RD Müller, T.D., Blucher, M., Chop, M.H. and DiMarchi, R.D. Anti-obesity drug discovery: progress and challenges. National The opening of the drug pastor. 21, 201–223 (2022). This review provides an insight into the problems of obesity, especially new concepts based on peptides.
Strohl, WR Fusion proteins to extend the half-life of biologics as the best strategy for biologics. Biopharmaceutics 29, 215–239 (2015).
Evans, M. et al. Adherence and persistence of antidiabetic drugs and association with clinical and economic outcomes in patients with type 2 diabetes: a systematic review of the literature. diabetic obesity. metabolism. 24, 377–390 (2022).
Polonsky, WH, Fisher, L., Hessler, D., Bruhn, D. & Best, JH Patient perspectives on once-weekly medications for diabetes. Polonsky, WH, Fisher, L., Hessler, D., Bruhn, D. & Best, JH Patient perspectives on once-weekly medications for diabetes. Polonsky W.H., Fisher L., Hessler D., Brune D., and Best J.H. A patient’s perspective on once-weekly diabetes medications. Polonsky, WH, Fisher, L., Hessler, D., Bruhn, D. & Best, JH 患者对每周一次的糖尿病药物的看法。 Polonsky, WH, Fisher, L., Hessler, D., Bruhn, D. & Best, JH Polonsky W.H., Fisher L., Hessler D., Brune D., and Best J.H. Patient perception of once-weekly diabetes medications. diabetic obesity. metabolism. 13, 144–149 (2011).
Hashimoto, M., Takada, K., Kiso, Y. & Muranishi, S. Synthesis of palmitoyl derivatives of insulin and their biological activities. Hashimoto, M., Takada, K., Kiso, Y. & Muranishi, S. Synthesis of palmitoyl derivatives of insulin and their biological activities. Hashimoto M., Takada K., Kiso Y. and Muranishi S. Synthesis of palmitoyl derivatives of insulin and their biological activity. Hashimoto, M., Takada, K., Kiso, Y. & Muranishi, S. 胰岛素棕榈酰衍生物的合成及其生物活性。 Hashimoto, M., Takada, K., Kiso, Y. & Muranishi, S. Synthesis and biological activity of insulin palmitoyl derivatives. Hashimoto M., Takada K., Kiso Y. and Muranishi S. Synthesis and biological activity of insulin palmitoyl derivatives. medicine reservoir 6, 171–176 (1989).
Kurtzhals, P. et al. Albumin binding to fatty acid-acylated insulin: characterization of ligand-protein interactions and correlation between binding affinity and insulin action time in vivo. biochem. J. 312, 725–731 (1995). This work is the first to demonstrate an increase in half-life due to the binding of albumin to peptides derived from fatty acids.
Mejuch, T. & Waldmann, H. Synthesis of lipidated proteins. Mejuch, T. & Waldmann, H. Synthesis of lipidated proteins. Meyukh, T. and Waldmann, H. Synthesis of lipidated proteins. Mejuch, T. & Waldmann, H. 脂化蛋白质的合成。 Mejuch,T. & Waldmann,H. Meyukh, T. and Waldmann, H. Synthesis of lipidated proteins. Bioconjugate. Chemical. 27, 1771–1783 (2016).
Chen, B., Sun, Y., Niu, J., Jarugumilli, GK & Wu, X. Protein lipidation in cell signaling and diseases: function, regulation, and therapeutic opportunities. Chen, B., Sun, Y., Niu, J., Jarugumilli, GK & Wu, X. Protein lipidation in cell signaling and diseases: function, regulation, and therapeutic opportunities. Chen B., Sun Y., Niu J., Jarugumilli G.K. and Wu X. Protein lipidation in cell signaling and disease: function, regulation, and therapeutic potential. Chen, B., Sun, Y., Niu, J., Jarugumilli, GK & Wu, X. 细胞信号和疾病中的蛋白质脂化：功能、调节和治疗机会。 Chen, B., Sun, Y., Niu, J., Jarugumilli, GK & Wu, X. Protein脂化 in cell signaling and disease: function, regulation and therapeutic opportunities. Chen B., Sun Y., Niu J., Jarugumilli G.K. and Wu X. Protein lipidation in cell signaling and disease: function, regulation, and therapeutic potential. cytochemistry. biology 25, 817–831 (2018).
Richter, WF, Bhansali, SG & Morris, ME Mechanistic determinants of biotherapeutics absorption following SC administration. Richter, WF, Bhansali, SG & Morris, ME Mechanistic determinants of biotherapeutics absorption following SC administration. Richter, V.F., Bhansali, S.G. and Morris, M.E. Mechanisms that determine the absorption of biotherapeutic agents after subcutaneous administration. Richter, WF, Bhansali, SG & Morris, ME SC 给药后生物治疗药物吸收的机制决定因素。 Richter, WF, Bhansali, SG & Morris, ME SC Richter, WF, Bhansali, SG & Morris, ME SC Механистические детерминанты абсорбции биотерапевтических препаратов после введения. Richter, WF, Bhansali, SG & Morris, ME SC Mechanistic determinants of absorption of biotherapeutic drugs after administration. AAPS J. 14, 559–570 (2012).
Gradel, AKJ et al. Factors affecting subcutaneous insulin absorption: implications for variability. J. Diabetes Res. 2018, 1205121 (2018).
Hildebrandt, P., Sejrsen, P., Nielsen, SL, Birch, K. & Sestoft, L. Diffusion and polymerization determines the insulin absorption from subcutaneous tissue in diabetic patients. Hildebrandt, P., Sejrsen, P., Nielsen, SL, Birch, K. & Sestoft, L. Diffusion and polymerization determines the insulin absorption from subcutaneous tissue in diabetic patients. Hildebrandt, P., Sejrsen, P., Nielsen, SL, Birch, K. & Sestoft, L. Диффузия и полимеризация определяют абсорбцию инсулина из подкожной ткани у пациентов с диабетом. Hildebrandt, P., Sejrsen, P., Nielsen, SL, Birch, K. & Sestoft, L. Diffusion and polymerization determine insulin absorption from subcutaneous tissue in diabetic patients. Hildebrandt, P., Sejrsen, P., Nielsen, SL, Birch, K. & Sestoft, L. 扩散和聚合决定了糖尿病患者皮下组织对胰岛素的吸收。 Hildebrandt, P., Sejrsen, P., Nielsen, SL, Birch, K. & Sestoft, L. Hildebrandt, P., Sejrsen, P., Nielsen, SL, Birch, K. & Sestoft, L. Диффузия и агрегация определяют абсорбцию инсулина подкожной тканью у пациентов с диабетом. Hildebrandt, P., Sejrsen, P., Nielsen, SL, Birch, K. & Sestoft, L. Diffusion and aggregation determine subcutaneous insulin absorption in diabetic patients. scanning. J. Klin. laboratory. invest. 45, 685–690 (1985).
Mosekilde, E., Jensen, KS, Binder, C., Pramming, S. & Thorsteinsson, B. Modeling absorption kinetics of subcutaneous injected soluble insulin. Mosekilde, E., Jensen, KS, Binder, C., Pramming, S. & Thorsteinsson, B. Modeling absorption kinetics of subcutaneous injected soluble insulin. Mosekilde E, Jensen KS, Binder S, Pramming S, and Thorsteinsson B. Modeling the absorption kinetics of subcutaneous soluble insulin. Mosekilde, E., Jensen, KS, Binder, C., Pramming, S. & Thorsteinsson, B. 模拟皮下注射可溶性胰岛素的吸收动力学。 Mosekilde, E., Jensen, KS, Binder, C., Pramming, S. & Thorsteinsson, B. Mosekilde E, Jensen KS, Binder S, Pramming S, and Thorsteinsson B. Modeling the absorption kinetics of subcutaneously administered soluble insulin. J. Pharmacokinetics. biopharmacy. 17, 67–87 (1989).
Kuna, M., Mahdi, F., Chade, AR & Bidwell, GL III Molecular size modulates pharmacokinetics, biodistribution, and renal deposition of the drug delivery biopolymer elastin-like polypeptide. Kuna, M., Mahdi, F., Chade, AR & Bidwell, GL III Molecular size modulates pharmacokinetics, biodistribution, and renal deposition of the drug delivery biopolymer elastin-like polypeptide. Kuna, M., Mahdi, F., Chade, AR & Bidwell, GL III Размер молекулы модулирует фармакокинетику, биораспределение и отложение в почках биополимерного эластиноподобного полипептида для доставки лекарственного средства. Kuna, M., Mahdi, F., Chade, AR & Bidwell, GL III Molecular size modulates pharmacokinetics, biodistribution, and renal deposition of biopolymeric elastin-like polypeptide for drug delivery. Kuna, M., Mahdi, F., Chade, AR & Bidwell, GL III 分子大小调节药物递送生物聚合物弹性蛋白样多肽的药代动力学、生物分布和肾脏沉积。 Kuna, M., Mahdi, F., Chade, AR & Bidwell, GL III Molecule 大小名行电影送送biological polymer elastic protein sample 多如乐的药代报学学、biological distribution和鈥脏气度。 Kuna, M., Mahdi, F., Chad, A.R. and Bidwell, G.L. III. Pharmacokinetics, biodistribution and renal deposition of biopolymeric elastin-like polypeptides modulating the size of the molecule. science Report 8, 7923 (2018).
Harris, JM, Martin, NE & Modi, M. Pegylation: a novel process for modifying pharmacokinetics. Harris, JM, Martin, NE & Modi, M. Pegylation: a novel process for modifying pharmacokinetics. Harris, JM, Martin, NE & Modi, M. Пегилирование: новый процесс модификации фармакокинетики. Harris, JM, Martin, NE & Modi, M. Pegylation: a novel process for modifying pharmacokinetics. Harris, JM, Martin, NE & Modi, M. 聚乙二醇化：一种改变药代动力学的新方法。 Harris, JM, Martin, NE & Modi, M. 聚乙二感化: a new method of changing medicine. Harris, JM, Martin, NE & Modi, M. Пегилирование: новый подход к изменению фармакокинетики. Harris, JM, Martin, NE & Modi, M. Pegylation: a new approach to changing pharmacokinetics. clinical. Pharmacokinetics. 40, 539–551 (2001).
Elmerer, M. et al. Measurement of interstitial albumin in human skeletal muscle and adipose tissue by open flow microperfusion. Yes. J. Physiology. endocrine. metabolism. 278, E352-E356 (2000).
Nelson, J. et al. The long half-life of albumin in humans requires an intact C-terminus. communicate. biology. 3, 181 (2020).
Chowdhury, K. et al. The Fc receptor (FcRn) for IgG associated with the major histocompatibility complex binds albumin and prolongs its lifespan. J. Exp. medicine. 197, 315–322 (2003).
Ober, RJ, Martinez, C., Lai, X., Zhou, J. & Ward, ES Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the single-molecule level. Ober, RJ, Martinez, C., Lai, X., Zhou, J. & Ward, ES Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the single-molecule level. Ober, RJ, Martinez, C., Lai, X., Zhou, J. & Ward, ES Экзоцитоз IgG, опосредованный рецептором FcRn: анализ на уровне одной молекулы. Ober, RJ, Martinez, C., Lai, X., Zhou, J. & Ward, ES FcRn receptor-mediated IgG exocytosis: single-molecule analysis. Ober, RJ, Martinez, C., Lai, X., Zhou, J. & Ward, ES 受体介导的IgG 胞吐作用，FcRn：单分子水平的分析。 Ober, RJ, Martinez, C., Lai, X., Zhou, J. & Ward, ES Ober, RJ, Martinez, C., Lai, X., Zhou, J. & Ward, Экзоцитоз IgG, опосредованный рецептором ES, FcRn: анализ на уровне одной молекулы. Ober, RJ, Martinez, C., Lai, X., Zhou, J. & Ward, ES receptor-mediated IgG exocytosis, FcRn: single molecule-level analysis. process. National Academy of Science. the science. US 101, 11076 (2004).
He, XM & Carter, DC Atomic structure and chemistry of human serum albumin. He, XM & Carter, DC Atomic structure and chemistry of human serum albumin. On, XM and Carter, DC Atomic structure and chemistry of human serum albumin. He, XM & Carter, DC 人血清白蛋白的原子结构和化学。 He, XM & Carter, DC. On, XM and Carter, DC Atomic structure and chemistry of human serum albumin. Nature 358, 209–215 (1992).
Curry, S., Mandelkow, H., Brick, P. & Franks, N. Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites. Curry, S., Mandelkow, H., Brick, P. & Franks, N. Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites. Curry S., Mandelkow H., Brick P. and Franks N. The crystal structure of human serum albumin in complex with a fatty acid shows an asymmetric distribution of binding sites. Curry, S., Mandelkow, H., Brick, P. & Franks, N. 与脂肪酸复合的人血清白蛋白的晶体结构揭示了结合位点的不对称分布。 Curry, S., Mandelkow, H., Brick, P. & Franks, N. The crystal structure of human serum white protein complex with fatty acids reveals an asymmetric distribution of binding sites. Curry S., Mandelkow H., Brick P. and Franks N. The crystal structure of human serum albumin in complex with fatty acids shows an asymmetric distribution of binding sites. Nat. structure. biology 5, 827–835 (1998). This paper presents the structural basis of binding of fatty acids to serum albumin.
Irby, D., Du, C. & Li, F. Lipid–drug conjugate for enhancing drug delivery. Irby, D., Du, C. & Li, F. Lipid–drug conjugate for enhancing drug delivery. Irby, D., Du, K. and Li, F. Lipid-drug conjugates for enhanced drug delivery. Irby, D., Du, C. & Li, F. Lipid-drug conjugate for enhance drug delivery。 Irby, D., Du, C. & Li, F. Lipid-drug conjugate for enhance drug delivery。 Irby, D., Du, K. and Li, F. Lipid-drug conjugate for enhanced drug delivery. Biochemistry 14, 1325–1338 (2017).
Torchilin V.P. Recent advances in the field of liposomes as drug carriers. National The opening of the drug pastor. 4, 145–160 (2005).
Bhat, M., Jatyan, R., Mittal, A., Mahato, RI & Chitkara, D. Opportunities and challenges of fatty acid conjugated therapeutics. Bhat, M., Jatyan, R., Mittal, A., Mahato, RI & Chitkara, D. Opportunities and challenges of fatty acid conjugated therapeutics. Bhat, M., Jatyan, R., Mittal, A., Mahato, R.I. and Chitkara, D. Opportunities and challenges of fatty acid conjugated therapeutics. Bhat, M., Jatyan, R., Mittal, A., Mahato, RI & Chitkara, D. 脂肪酸共轭疗法的机遇和挑战。 Bhat, M., Jatyan, R., Mittal, A., Mahato, RI & Chitkara, D. Fatty acid 共续电影的机遇和challenge. Bhat M., Jatyan R., Mittal A., Mahato R. I. and Chitkara D. Possibilities and challenges of fatty acid conjugation therapy. Chemical. physics Lipids 236, 105053 (2021).
Smith, R. & Tanford, C. Hydrophobicity of long chain n-alkyl carboxylic acids, as measured by their distribution between heptane and aqueous solutions. Smith, R. & Tanford, C. Hydrophobicity of long chain n-alkyl carboxylic acids, as measured by their distribution between heptane and aqueous solutions. Smith, R. and Tanford, K. Hydrophobicity of long-chain n-alkylcarboxylic acids measured by their distribution between heptane and aqueous solutions. Smith, R. & Tanford, C. 长链正烷基羧酸的疏水性，通过它们在庚烷和水溶液之间的分布来测量。 Smith, R. & Tanford, C. The hydrophobicity of 长链正alkylcarboxylate, measured by their distribution between hydrogen peroxide and aqueous solution. Smith, R. and Tanford, K. Hydrophobicity of long-chain n-alkylcarboxylic acids measured by their distribution between heptane and aqueous solutions. process. National Academy of Sciences. science US 70, 289 (1973).
Liu, J. et al. Once-weekly discovery of semaglutide analog of glucagon-like peptide-1 (GLP-1). J. Medicine. Chemical. 58, 7370–7380 (2015). This work demonstrates for the first time the possibility of using once a week fatty acid derivatization methods.
Østergaard, S. et al. Effect of human PYY3-36 dibasic fatty acid acylation on mini-pig Y2 receptor activity and half-life. the science. Report 11, 21179 (2021). This article demonstrates the importance of fatty acid position, linker and backbone stability in the development of long half-life PYY analogs.
Ensenat-Vaser, R. et al. Penetration of myristoylated peptides across the cell membrane was directly observed using confocal fluorescence microscopy. IUBMB Life 54, 33–36 (2002).
Nelson, AR, Borland, L., Allbritton, NL & Sims, CE Myristoyl-based transport of peptides into living cells. Nelson, AR, Borland, L., Allbritton, NL & Sims, CE Myristoyl-based transport of peptides into living cells. Nelson AR, Borland L, Allbritton NL. and Sims S.E. Peptide transport in living cells is based on myristoyl. Nelson, AR, Borland, L., Allbritton, NL & Sims, CE 基于肉豆蔻酰的肽转运到活细胞中。 Nelson, AR, Borland, L., Allbritton, NL & Sims, CE. Nelson, AR, Borland, L., Albritton, NL. and Sims, K.E. Transport of myristoyl-based peptides into living cells. Biochemistry 46, 14771–14781 (2007).
Kabanov, AV, Levashov, AV & Alakhov, VY Lipid modification of proteins and their membrane transport. Kabanov, AV, Levashov, AV & Alakhov, VY Lipid modification of proteins and their membrane transport. Kabanov A.V., Levashov A.V., Alakhov V.Yu. Lipid modification of proteins and their membrane transport. Kabanov, AV, Levashov, AV & Alakhov, VY 蛋白质的脂质修饰及其膜转运。 Kabanov, AV, Levashov, AV & Alakhov, VY Kabanov A.V., Levashov A.V., Alakhov, Lipid modification of VY proteins and their membrane transport. protein engineering. Dec. Searl. 3, 39–42 (1989).
Gao, X., Mazière, AD, Beard, R., Klumperman, J. & Hannoush, RN Fatty acylation enhances the cellular internalization and cytosolic distribution of a cystine-knot peptide. Gao, X., Mazière, AD, Beard, R., Klumperman, J. & Hannoush, RN Fatty acylation enhances the cellular internalization and cytosolic distribution of a cystine-knot peptide. Gao, X., Mazier, A.D., Byrd, R., Klumperman, J. and Hannoosh, R.N. Fatty acid acylation enhances cellular internalization and cytosolic distribution of a peptide with a cystine loop. Gao, X., Mazière, AD, Beard, R., Klumperman, J. & Hannoush, RN 脂肪酰化增强了胱氨酸结肽的细胞内化和胞质分布。 Gao, X., Mazière, AD, Beard, R., Klumperman, J. & Hannoush, RN. Gao, X., Mazier, A.D., Byrd, R., Klumperman, J. and Hannoosh, R.N. Fatty acylation enhances cellular internalization and cytoplasmic distribution of cystine peptides. iScience 24, 103220 (2021).
Baker, E.M. et al. Half-life-prolonging modification of the YY3-36 peptide for direct receptor-mediated internalization. Moore. medicine. 16, 3665–3677 (2019).
Mäde, V., Bellmann-Sickert, K., Kaiser, A., Meiler, J. & Beck-Sickinger, AG Position and length of fatty acids strongly affect receptor selectivity pattern of human pancreatic polypeptide analogues. Mäde, V., Bellmann-Sickert, K., Kaiser, A., Meiler, J. & Beck-Sickinger, AG Position and length of fatty acids strongly affect receptor selectivity pattern of human pancreatic polypeptide analogues. Made, W., Bellmann-Sickert, K., Kaiser, A., Mailer, J. and Beck-Sickinger, A.G. The position and length of fatty acids strongly influence the selectivity pattern of human pancreatic polypeptide analog receptors. Mäde, V., Bellmann-Sickert, K., Kaiser, A., Meiler, J. & Beck-Sickinger, AG 脂肪酸的位置和长度强烈影响人胰腺多肽类似物的受体选择性模式。 Mäde, V., Bellmann-Sickert, K., Kaiser, A., Meiler, J. & Beck-Sickinger, AG Made, W., Bellmann-Sickert, K., Kaiser, A., Mailer, J. and Beck-Sickinger, A.G. The position and length of fatty acids strongly influence the selectivity pattern of human pancreatic analog polypeptide receptors. HimMedChem 9, 2463–2474 (2014).
Aleksopoulou, F. et al. The lipid metabolite PrRP31 is a long-acting dual GPR10 and NPFF2 receptor agonist with potent weight loss effects. the science. Report 12, 1696 (2022). This methodological study highlights the differences between mono- and diacid side chains.
Poulsen, K. et al. Rational development of stable agonists of the Y2 receptor peptide PYY3-36. medicine. storage tank. 38, 1369–1385 (2021).
Conde-Frieboes, K. et al. Identification and characterization of in vitro and in vivo analogues of long-acting and selective melanocortin 4 receptor (MC4-R) alpha-melanocyte-stimulating hormone (alpha-MSH). J. Medicine. Chemical. 55, 1969–1977 (2012).
Ramirez-Andersen, HS et al. Long-acting human growth hormone analogues bound to non-covalent albumin. Bioconjugate. Chemical. 29, 3129–3143 (2018).
Madsen, K. et al. Structure-activity relationship and elongation of long-acting glucagon-like peptide-1 derivatives: the importance of fatty acid length, polarity, and volume. J. Medicine. Chemical. 50, 6126–6132 (2007).
Wieczorek, B., Spetzler, JC, Kruse, T., Linderoth, L. & Kofoed, J. Double-acylated GLP-1 derivatives. Wieczorek, B., Spetzler, JC, Kruse, T., Linderoth, L. & Kofoed, J. Double-acylated GLP-1 derivatives. Wieczorek, B., Spetzler, JC, Kruse, T., Linderoth, L. & Kofoed, J. Дважды ацилированные производные GLP-1. Wieczorek, B., Spetzler, JC, Kruse, T., Linderoth, L. & Kofoed, J. Doubly acylated derivatives of GLP-1. Wieczorek, B., Spetzler, JC, Kruse, T., Linderoth, L. & Kofoed, J. 双酰化GLP-1 衍生物。 Wieczorek, B., Spetzler, JC, Kruse, T., Linderoth, L. & Kofoed, J. 双酰化GLP-1 衍生物。 Wieczorek, B., Spetzler, JC, Kruse, T., Linderoth, L. & Kofoed, J. Диацилированные производные GLP-1. Wieczorek, B., Spetzler, JC, Kruse, T., Linderoth, L. & Kofoed, J. Diacylated derivatives of GLP-1. US Patent WO2012/140117 (2012).
Young, P.-Yu. Wait. Potent, long-acting GLP-1 analogs designed for transdermal delivery based on microstructure. process. National Academy of Science. the science. US 113, 4140–4145 (2016).
Royalty, JE, Konradsen, G., Eskerod, O., Wulff, BS & Hansen, BS Investigation of safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of a long-acting α-MSH analog in healthy overweight and obese subjects. Royalty, JE, Konradsen, G., Eskerod, O., Wulff, BS & Hansen, BS Investigation of safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of a long-acting α-MSH analog in healthy overweight and obese subjects. Royalty, J. E., Konradsen, G., Eskerod, O., Wolf, B. S. and Hansen, B. S. Safety, tolerability, pharmacokinetics, and pharmacodynamics study of single and multiple doses of long-acting α-MSG analog in healthy overweight and obese subjects.版税, JE, Konradsen, G., Eskerod, O., Wulff, BS & Hansen, BS 单剂量和多剂量长效α-MSH 类似物在健康超重和肥胖患者中的安全性、耐受性、药代动力学和药效学研究科目。版税, JE, Konradsen, G., Eskerod, O., Wulff, BS & Hansen, BS Single dosage and multi dosage long effect α-MSH 全健康超重和肥胖可以中可以可以而受性、药代报学学和药效学研究科目。 Royalty, J. E., Konradsen, G., Eskerod, O., Wolf, B. S. and Hansen, B. S. Safety, tolerability, pharmacokinetics of single and multiple doses of long-acting alpha-MSG analogues in healthy overweight and obese subjects. Kinetics and pharmacodynamics. J. Clin. Pharmacodynamics. 54, 394–404 (2014).
Lau, J., F., Kruse, T., Linderoth, L. & Thøgersen, H. Novel glucagon analogues. Lau, J., F., Kruse, T., Linderoth, L. & Thøgersen, H. Novel glucagon analogues. Lau, J., F., Kruse, T., Linderoth, L. and Togersen, H. New glucagon analogues. Lau, J., F., Kruse, T., Linderoth, L. & Thøgersen, H. 新型胰高血糖素类似物。 Lau, J., F., Kruse, T., Linderoth, L. & Thøgersen, H. Lau, J., F., Cruz, T., Linderoth, L. and Togersen, H. New glucagon analogues. US Patent WO2011/117416 A1 (2011).
Ward, BP et al. Lipidation of peptides stabilizes structures to enhance biological function. Moore. metabolism. 2, 468–479 (2013). This work demonstrates the role of fatty acid side chains in determining the structural stability and binding of peptide drug receptors.
Koskun T. et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes: from discovery to clinical proof of concept. Moore. metabolism. 18, 3-14 (2018). This paper presents the design of the first fatty acid-derived GLP-1/GIP co-agonist for once-weekly administration in the clinic.
Kjeldsen, T.B. et al. Molecular engineering of icodec insulin, the first once-weekly acylated insulin analog in humans. J. Medicine. Chemical. 64, 8942–8950 (2021). This paper presents the first development of fatty acid derived insulin for once weekly administration.
van Witteloostein, S.B. et al. Neoglycolipids for long-acting peptides: self-assembling analogs of glucagon-like peptide 1 with albumin-binding properties and high in vivo potency. Moore. medicine. 14, 193–205 (2017).
Zorzi, A., Middendorp, SJ, Wilbs, J., Deyle, K. & Heinis, C. Acylated heptapeptide binds albumin with high affinity and application as tag furnishes long-acting peptides. Zorzi, A., Middendorp, SJ, Wilbs, J., Deyle, K. & Heinis, C. Acylated heptapeptide binds albumin with high affinity and application as tag furnishes long-acting peptides. Zorzi, A., Middendorp, S.J., Wilbs, J., Dale, K. and Haynes, S. Acylated heptapeptide binds albumin with high affinity, and its use as a label provides a long-acting peptide. Zorzi, A., Middendorp, SJ, Wilbs, J., Deyle, K. & Heinis, C. 酰化七肽以高亲和力结合白蛋白，并作为标签提供长效肽。 Zorzi, A., Middendorp, SJ, Wilbs, J., Deyle, K. & Heinis, C. 鎄化七peptide以高亲和力设计白白约筒，使用于设计手机长整线等。 Zorzi, A., Middendorp, S.J., Wilbs, J., Dale, K. and Haynes, S. Acylated heptapeptides bind albumin with high affinity and serve as labels for long-acting peptide delivery. Nat. communicate 8, 16092 (2017).